, /PRNewswire/ — Woolsey Pharmaceuticals today announced the recent issuance of three key patents that cover cutting-edge innovations related to its drug BRAVYL® (oral fasudil) in the treatment of sporadic Amyotrophic Lateral Sclerosis (ALS) and the development of advanced dysphagia-friendly formulations to improve patient care.
US patent 11,779,588 protects the company’s proprietary approach in using oral fasudil, a Rho-kinase inhibitor, to target disease progression in ALS patients, and includes a claim “A method of treating a patient with sporadic amyotrophic lateral sclerosis (ALS), comprising orally administering a therapeutically effective amount of a fasudil or hydroxyfasudil (M3), or a pharmaceutically acceptable salt thereof, to the patient.” By focusing on sporadic ALS — which encompasses 90-95% of all cases — this patent provides us with protection for the use of fasudil in the vast majority of the population affected by this devastating neurodegenerative condition.
US patents 11,944,633 and 12,115,167 cover, among other …